Roche: Tecentriq cocktail slows kidney cancer progression
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Health | Immunotherapy | Kidney Cancer | Switzerland Health | Urology & Nephrology